David A. Siegel Xenetic Biosciences, Inc. Transaction History

Two Sigma Advisers, LP

  • $42.5 Billion
  • Q1 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022
SELL
$0.88 - $1.37 $21,472 - $33,428
-24,400 Closed
0 $0
Q4 2021

Feb 14, 2022
SELL
$1.27 - $2.08 $165,989 - $271,856
-130,700 Reduced 84.27%
24,400 $31,000
Q3 2021

Nov 15, 2021
BUY
$1.73 - $5.3 $268,323 - $822,030
155,100 New
155,100 $318,000

About Xenetic Biosciences, Inc.

XBIO Quotes by TradingView
  • Ticker XBIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,166,600
  • Market Cap $61.7M
  • Description
  • Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-base...
More about XBIO
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email